1 / 41

Cancer and Neuropathic Pain

Cancer and Neuropathic Pain. Mike Bennett Professor of Palliative Medicine Lancaster University. Case history. 52 year old man Six month history of colon cancer Recent progression on chemotherapy liver and lung metastases. Case history.

dian
Download Presentation

Cancer and Neuropathic Pain

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cancer and Neuropathic Pain Mike Bennett Professor of Palliative Medicine Lancaster University

  2. Case history • 52 year old man • Six month history of colon cancer • Recent progression on chemotherapy • liver and lung metastases

  3. Case history • Presents to your clinic with mass in left chest wall • constant aching pains in chest • occasional paroxysmal pain radiating around chest • dysaesthesias over left chest wall • non-tender mass but dynamic mechanical allodynia in T7-8 dermatomes

  4. Hb = 9.4 WCC = 4 (1.2 neut) Plat = 117 Barthel score = 72 / 100 Pain helped initially by codeine, but pain now more intense

  5. TASK • What is your pain diagnosis? • any other information needed • What other investigations or assessments would you request? • What is your management plan? • What is your main outcome measure of success?

  6. Neuropathic painDefinitions • Neuropathic pain • Pain arising as a direct consequence of a lesion or disease affecting the somatosensory system • = abnormal activation of pain pathways • Nociceptive pain • inflammatory pain • normal activation of pain pathways.

  7. Neuropathic painKey features • Symptoms • Spontaneous pains (pain without stimulation) • Continuous = dysaethesias; burning, tingling • Paroxysmal = shooting, electric shocks • Evoked pains • ‘hypersensitive skin’; can’t bear to be touched

  8. Neuropathic painKey features • Signs • Abnormal response to stimulation • Allodynia = pain after non-noxious stimulus • Hyperalgesia = exaggerated pain after noxious stimulus • Hyperpathia = temporal and spatial abnormalities • Loss of sensation • Autonomic changes • Mottled, flushed, sweating

  9. Mechanisms • Peripheral • nociceptor sensitization • abnormal axonal responses • Central • disinhibition • hyperexcitability

  10. Neuropathic pain in cancer- the issues • Epidemiology • Assessment • is it different to NeuP in non-cancer patients? • how to recognise it • patient related factors • Management principles

  11. Epidemiology • Neuropathic pain probably affects 40% of patients with cancer pain • vast majority have mixed mechanism pain • …and is associated with greater pain intensity Caraceni and Portenoy Pain 1999 Grond et al Pain 1999

  12. Epidemiology • Compared with nociceptive pain: • less pain relief with single doses of opioids • more likely to escalate opioid doses • likely to have poorer outcome with treatment • ….even spinal analgesia is less effective Cherny et al Neurology 1994 Vigano et al Cancer 1998 Mercadante et al 2000 Supp Care Cancer Becker et al 2000 Stereo Funct Neurosurg

  13. Epidemiology • Aetiology • direct effects of cancer • indirect effects of cancer • cancer treatment • co-morbid conditions

  14. Assessment • Clinically • pains are often mixed, evolving quickly • Pathologically • similar peripheral and spinal mechanisms as in non-cancer patients • Pharmacologically • frail patients; cognitive, hepatic and renal impairment • Psychologically • preparing for prognosis of weeks to months

  15. Assessment • Patterns of pain are varied • slowly evolving over weeks • acute on chronic exacerbation over days • sudden onset • Screen for cognitive, hepatic and renal impairment

  16. Assessment • Are neuropathic mechanisms present? • Pain in an area of altered sensation Glynn Pall Med 1989 • Positive and negative phenomena Ochoa 1987 • LANSS Pain Scale Bennett Pain 2001 • S-LANSS (self report LANSS) Bennett et al J Pain 2005

  17. Diagnosis is clinically based • Screening tools exist • LANSS pain scale • 7 item tool • 5 questions, 2 examination items • Validated • worldwide • in variety of chronic pain states

  18. AssessmentCurrent screening tools • Content • short lists of classic descriptors or symptoms • some have brief clinical examination • Usually physician administered • but several patient self-report versions • Easy to complete • total score suggests presence or absence of neuropathic pain mechanisms

  19. AssessmentCurrent screening tools • LANSS and S-LANSS • Bennett, Pain 2001 • Bennett et al, J Pain 2005 • Neuropathic Pain Questionnaire (NPQ) • Krause, Backonja, Clin J Pain 2003 • DN4 • Bouhassira et al, Pain 2005 • ID Pain • Portenoy, Curr Med Res Opin 2006 • PainDetect • Freynhagen et al , Curr Med Res Opin 2006

  20. Common Features of Screening Tools

  21. Clinician Certainty Ratings of Presence of Neuropathic Pain 20 SD = 35.6Mean = 48.9N = 200 10 0 0 10 20 30 40 50 60 70 80 90 100 Clinician VAS Score Bennett et al. Pain. 2006;122:289-94.

  22. Certainty of clinician ratings, S-LANSS score, and composite NPS score (median, IQR)

  23. Assessment • Neuropathic pain mechanisms / symptoms exist as a spectrum • More useful concept (esp in cancer pain) • ‘Pain of predominantly neuropathic origin’

  24. Management • Diagnose pain • Use multimodal approach • Conventional drugs and routes help but alternatives are often necessary • this means opioids plus co-analgesics

  25. ManagementNeuropathic pain and cancer • The difference is in the patient not the pain • more frail • changing pain picture • additional renal, hepatic or cognitive impairment • Toxicity may be reached before benefit • NNT may be higher • NNH may be lower

  26. Management • 593 cancer pain patients treated with WHO guidelines (opioids +/- co-analgesia) • NeuP no more intense than nociceptive group • 96% had opioids • 53% had adjuvants (sig more than nocicept group) • VAS decreased from 70mm to 28mm Grond et al Pain 1999

  27. ManagementNNT and evidence based ladders • Note that ‘50% pain relief’ can mean: • 50% reduction in VAS where measured • ‘excellent or good’ relief • but also ‘moderate’ relief • Confidence intervals of NNTs important too • SSRIs 6.7 (3.4 - 435) • Don’t forget NNH

  28. BMJ 15 August 2009, Volume 339

  29. ManagementNNT and evidence based ladders • WHO ladder • morphine 2.5 • oxycodone 2.6 • Tricyclics • amitriptyline group 2.0, NNH 3.7 • Antiepileptics • gabapentin NNT 3.5, NNH 2.5 • or carbamazepine better? (NNT 2.3, NNH 3.7)

  30. A pragmatic approach A. Initial steps 3. GABAPENTIN [add in or replace] 2. AMITRIPTYLINE [add in or replace] 1. WHO LADDER

  31. A pragmatic approach B. Advanced steps ‘The unlit loft at the top of the ladder’ 6. METHADONE [or other opioid switch] 5. ANAESTHETIC APPROACHES 4. KETAMINE [with opioid]

  32. Treatment • What you can do……. • WHO ladder works for many patients • no opioid is superior to another, just different • Add in co-analgesics • Antidepressants = amitriptyline, duloxetine • Antiepileptics = gabapentin, pregabalin

  33. When to contact palliative care • Opioid switching, esp methadone • Ketamine • Inpatient admission for • clinical assessment by specialist team • managing distress • family support

  34. When palliative care teams contact pain teams • intercostal blocks • paravertebral blocks • spinal opioid infusions

  35. When pain teams contact neurosurgeons • Cordotomy

  36. SummaryNeuropathic mechanisms in cancer pain: • are common • often present as a spectrum with nociceptive mechanisms • are caused by cancer and its treatment • are sometimes accompanied by cognitive, hepatic and renal impairment • can usually be effectively treated with opioids and co-analgesics, but sometimes need specialist help

  37. Thank you m.i.bennett@lancaster.ac.uk

More Related